Preventative and therapeutic effects of a novel humanized anti-glycoprotein Ibα fragment of antigen-binding region in a murine model of thrombotic thrombocytopenic purpura
CA1001 can effectively inhibit VWF-platelet interaction and thrombus formation under various (patho)physiological conditions. Thus, CA1001 may be a potential candidate for further development as a novel therapeutic for immune-mediated and hereditary TTP and perhaps for other inflammatory thrombotic disorders such as ischemic stroke.
Authors
- Sladjana Slavkovic (ORCID: https://orcid.org/0000-0002-6927-1154)
- Zhijian Wu (ORCID: https://orcid.org/0000-0002-7189-3358)
- X. Long Zheng (ORCID: https://orcid.org/0000-0003-1680-5295)
- Zhenze Liu (ORCID: https://orcid.org/0000-0001-8326-3698)
- Liang Zheng (ORCID: https://orcid.org/0000-0003-4143-1635)
- Heyu Ni (ORCID: https://orcid.org/0000-0002-7621-2945)
- Miguel A. D. Neves (ORCID: https://orcid.org/0000-0002-2220-486X)
- Reheman Adili (ORCID: https://orcid.org/0000-0002-1973-9695)
- Quan Zhang (ORCID: https://orcid.org/0000-0002-9776-2401)
- Guangheng Zhu
- Xi Lei
- Wenjing Ma (ORCID: https://orcid.org/0000-0001-7981-0716)
- Xiaohong Xu (ORCID: https://orcid.org/0000-0002-3860-9845)
Institutions
- St. Michael's Hospital (CA)
- Central South University (CN)
- The University of Kansas Health System (US)
- University of Kansas Medical Center (US)
- Second Xiangya Hospital of Central South University (CN)
- Canadian Blood Services (CA)
Publication Details
- Journal
- Journal of Thrombosis and Haemostasis
- Published
- 2025-02-15
- DOI
- https://doi.org/10.1016/j.jtha.2025.02.009
- Citations
- 2
- Primary Topic
- Complement system in diseases
- Type
- article
- Field-Weighted Citation Impact
- 1.59
Funders
- American Heart Association
- National Heart, Lung, and Blood Institute